USARx offers the following ways to purchase this medication. Choose the Best option for you!
Pay this amount and pick up your prescription at ANY Retail pharmacy of your choice! Walgreens, CVS, Walmart, etc.
The easiest way to receive your medications.
Yes100% of Medicare Part D and Medicare Advantage plans cover this drug.
It depends. Which coverage stage are you in? Click on a tab below…
FREE – $17
In the Deductible co-pay stage, you are responsible for the full cost of your prescriptions. Your Medicare deductible cannot exceed $360 in 2016.
Here are some ways that may lower the cost of your montelukast sodium prescription.
If your Medicare co-pay is higher, you can save money by using a USARx coupon instead.
Applies to montelukast: oral packet, oral tablet, oral tablet chewable
Along with its needed effects, montelukast may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking montelukast:
Incidence not known
Some side effects of montelukast may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Incidence not known
For Healthcare Professionals
Applies to montelukast: oral granule, oral tablet, oral tablet chewableGeneral
The most common adverse reactions (incidence more than 5% and greater than placebo) were: Upper respiratory infection, fever, headache, pharyngitis, cough, abdominal pain, diarrhea, otitis media, influenza, rhinorrhea, sinusitis, otitis.Immunologic
Very rare (less than 0.01%): Churg-Strauss Syndrome
Churg-Strauss syndrome is a rare granulomatous eosinophilic condition that involves the upper and lower airways and manifests as rhinitis, sinusitis and asthma. If untreated the syndrome may progress to systemic vasculitis, peripheral neuropathy and potentially fatal cardiac complications. In most cases, the condition emerged during withdrawal of oral corticosteroid therapy. A causative role for leukotriene receptor antagonists has not been ruled out.Nervous system
Very common (10% or more): Headache (18.4%)
Common (1% to 10%): Dizziness (1.9%)
Postmarketing reports: Disturbance in attention, irritability, memory impairment, tremor, drowsiness, paraesthesia/hypoesthesia, seizuresDermatologic
Common (1% to 10%): Rash (1.6%), atopic dermatitis, skin infection, eczema, urticaria
Postmarketing reports: Angioedema, bruising, erythema multiforme, erythema nodosum, pruritus, Stevens-Johnson syndrome/toxic epidermal necrolysisGastrointestinal
Common (1% to 10%): Abdominal pain (2.9%), dyspepsia (2.1%), dental pain (1.7%), gastroenteritis (1.5%), nausea, diarrhea, dyspepsia, gastroenteritis, tooth infectionHepatic
Common (1% to 10%): ALT increase (2.1%), AST increased (1.6%)
Postmarketing reports: Hepatic eosinophilic infiltration; cases of cholestatic hepatitis, hepatocellular liver-injury, and mixed-pattern liver injury. Most of these occurred in combination with other confounding factors, such as use of other medications, or when administered to patients who had underlying potential for liver disease such as alcohol use or other forms of hepatitis.Ocular
Common (1% to 10%): Myopia, conjunctivitisOther
Common (1% to 10%): Asthenia, fatigue (1.8%), fever (1.5%), trauma (1%), influenza, fever, otitis, viral infection, varicella, ear pain, otitis media
Uncommon (0.1% to 1%): Malaise
Postmarketing reports: EdemaRespiratory
Common (1% to 10%): Influenza (4.2%), cough (2.7%), nasal congestion (1.6%), pharyngitis, sinusitis, laryngitis, infective rhinitis, acute bronchitis, rhinorrhea, pneumonia, upper respiratory infection, wheezing, tonsillitis
Postmarketing reports: Epistaxis, pulmonary eosinophiliaCardiovascular
Postmarketing reports: PalpitationsGenitourinary
Postmarketing reports: Enuresis in childrenHematologic
Postmarketing reports: Increased bleeding tendency, thrombocytopeniaHypersensitivity
Postmarketing reports: AnaphylaxisMusculoskeletal
Postmarketing reports: Arthralgia, myalgia including muscle crampsPsychiatric
Postmarketing reports: Agitation including aggressive behavior or hostility, anxiousness, depression, disorientation, dream abnormalities, hallucinations, insomnia, restlessness, somnambulism, suicidal thinking and behavior (including suicide)
November 24, 2020
December 2, 2020
November 15, 2020
December 2, 2020
December 1, 2020
October 19, 2020